I stay at home and look after the children tylenol childrens Afatinib's safety and effectiveness were evaluated in clinical studies involving 345 people with spreading NSCLC whose tumors had EGFR mutations. Among those who received afatinib, progression-free survival was 4.2 months longer than for those who received chemotherapy, the FDA said. There was no statistically significant difference in overall survival, the agency added.
|